Journey Medical achieved strong year-over-year revenue growth in Q3 2025, largely fueled by the launch and commercial momentum of Emrosi. Despite higher revenues and improving margins, the company reported a net loss of $2.3M.

Journey Medical posted $15 million in revenue during Q2 2025, driven in part by Emrosi's initial commercial performance. Gross margin improved to 67% and adjusted EBITDA loss narrowed to $0.5 million. However, the company recorded a net loss of $3.8 million for the quarter.

Journey Medical generated $13.1 million in net revenue for Q1 2025, supported by a $2.1 million contribution from the commercial launch of Emrosi. Despite flat revenue year-over-year, the company improved its gross margin to 64% and reduced its overall net loss. Operating expenses were driven by Emrosi-related sales activity, with no R&D spending in the quarter.

Journey Medical posted a surprise profit in Q4 2024, reversing previous losses. Revenue came in at $13.6M and the company reported net income of $1.5M, helped by lower R&D spend and tight SG&A management. The Emrosi launch remains a key catalyst for 2025.

Journey Medical reported solid third quarter 2024 results with total revenues of $14.6 million and highlighted the FDA approval of Emrosi™ for the treatment of inflammatory lesions of rosacea in adults, with launch expected in late Q1 or early Q2 of 2025.

Journey Medical reported a 14% sequential increase in total net product revenue, reaching $14.9 million, and positive Adjusted EBITDA for the second quarter of 2024. The company is focused on its core dermatology franchise and the upcoming launch of DFD-29.

Journey Medical reported a 7% increase in total revenues for the first quarter ended March 31, 2024, reaching $13.0 million compared to $12.2 million in the first quarter of 2023. The company also made significant progress with its DFD-29 development program, with the FDA accepting the New Drug Application and assigning a PDUFA goal date of November 4, 2024.

Journey Medical Corporation reported full-year revenue of $79.2 million, a 7% increase from 2022. The company achieved $15.6 million in operating cost savings, exceeding initial guidance. A New Drug Application for DFD-29 was accepted by the FDA, with a PDUFA goal date of November 4, 2024.

Journey Medical Corporation reported a substantial increase in total net revenues for Q3 2023, reaching $34.5 million, a 101% increase compared to the previous quarter and a 114% increase compared to Q3 2022. The company also achieved GAAP net income of $16.8 million, a significant improvement from the net loss of $10.1 million in the same quarter of the previous year. This performance was boosted by an upfront payment from an exclusive license agreement with Maruho Co., Ltd.

Journey Medical Corporation reported a 41% increase in total net revenues, reaching $17.2 million in the second quarter of 2023 compared to $12.2 million in the first quarter. The company also announced positive topline results from two Phase 3 clinical trials evaluating DFD-29.

Journey Medical reported total revenues of $12.2 million for the first quarter of 2023, with net product revenues impacted by higher gross-to-net adjustments and lower unit sales volumes for certain products, although an improvement was seen in April.

Journey Medical reported its Q4 and full year 2022 financial results, highlighting revenue growth for Qbrexza and Accutane, along with contributions from Amzeeq and Zilxi, which accounted for approximately 77% of the total revenue for the year.

Journey Medical reported a decrease in revenue for Q3 2022 compared to Q3 2021, primarily due to generic competition of Targadox. However, the company is progressing with its DFD-29 Phase 3 clinical program and anticipates top-line data in the first half of 2023.

Journey Medical reported record net product revenues of $63.1 million for the full year 2021 and completed its initial public offering, raising $30.6 million in net proceeds.